Unknown PHASE1 INTERVENTIONAL 1-arm NCT02930967

Chimeric Switch Receptor Modified T Cells for Patients With PD-L1+ Recurrent or Metastatic Malignant Tumors

A Safety and Efficacy Study of Chimeric Switch Receptor Modified T Cells in Patients With Recurrent or Metastatic Malignant Tumors

Sponsor: China Meitan General Hospital

Conditions Metastatic PD-L1+ Malignant Tumors Recurrent PD-L1+ Malignant Tumors

Interventions autologous CSR T

Updated 6 times since 2017 Last updated: Oct 11, 2016 Started: Aug 31, 2016 Primary completion: Aug 31, 2018 Completion: Aug 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Metastatic PD-L1+ Malignant Tumors and Recurrent PD-L1+ Malignant Tumors and is currently ongoing. China Meitan General Hospital leads this study, which shows 6 recorded versions since 2016 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Unknown PHASE1
Jul 2024 — Sep 2024 [monthly]

Unknown PHASE1

Status: Unknown Status → Unknown
Jan 2021 — Jul 2024 [monthly]

Unknown Status PHASE1
Sep 2019 — Jan 2021 [monthly]

Unknown Status PHASE1

Status: Recruiting → Unknown Status
Jun 2018 — Sep 2019 [monthly]

Recruiting PHASE1

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Recruiting PHASE1

First recorded

Aug 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

China Meitan General Hospital
Marino Biotechnology Co., Ltd.

Data source: China Meitan General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China